Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 21 February 2024) Immunocore Holdings plc (Nasdaq:IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report full year 2023 results, before the US markets open on Wednesday, February 28, 2024. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. ET (1:00 p.m. GMT) to discuss their financial results and provide a business and portfolio update.